Home/Filings/4/0001140361-18-011646
4//SEC Filing

Suzdak Peter David 4

Accession 0001140361-18-011646

CIK 0001228627other

Filed

Mar 1, 7:00 PM ET

Accepted

Mar 2, 4:26 PM ET

Size

6.8 KB

Accession

0001140361-18-011646

Insider Transaction Report

Form 4
Period: 2018-02-28
Suzdak Peter David
Chief Executive Officer
Transactions
  • Exercise/Conversion

    Restricted Stock Units

    2018-02-28+6,25018,750 total
    Common Stock (6,250 underlying)
  • Exercise/Conversion

    Common Stock

    2018-02-28+6,25022,250 total
Footnotes (2)
  • [F1]Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock.
  • [F2]On January 20, 2017, the reporting person was granted 25,000 RSUs, of which 6,250 vested on February 28, 2018. The remaining RSUs will vest in three equal annual installments on the last business day in February, beginning February 28, 2019.

Issuer

REXAHN PHARMACEUTICALS, INC.

CIK 0001228627

Entity typeother

Related Parties

1
  • filerCIK 0001296629

Filing Metadata

Form type
4
Filed
Mar 1, 7:00 PM ET
Accepted
Mar 2, 4:26 PM ET
Size
6.8 KB